Vical to Present at JMP Securities Healthcare Conference

Vical to Present at JMP Securities Healthcare Conference

SAN DIEGO, July 5, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL)
today announced that the company will provide an overview of its technologies,
development programs, and outlook on Thursday, July 12, at 3:30 p.m. ET at the
JMP Securities Healthcare Conference (New York, July 12 – 13).

A webcast of Vical's presentation will be available live and archived through
the Events & Presentations page in the Investors section of the Vical website

About Vical

Vical researches and develops biopharmaceutical products based on its patented
DNA delivery technologies for the prevention and treatment of serious or
life-threatening diseases. Potential applications of the company's DNA
delivery technology include DNA vaccines for infectious diseases or cancer, in
which the expressed protein is an immunogen; cancer immunotherapeutics, in
which the expressed protein is an immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an angiogenic growth factor. The
company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major
pharmaceutical companies and biotechnology companies that give it access to
complementary technologies or greater resources. These strategic partnerships
provide the company with mutually beneficial opportunities to expand its
product pipeline and address significant unmet medical needs. Additional
information on Vical is available at

The Vical Incorporated logo is available at

This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those
projected. Forward-looking statements include statements about the company's
focus, collaborative partners, product candidates, and developmental status.
Risks and uncertainties include whether any product candidates will be shown
to be safe and efficacious in clinical trials, the timing of clinical trials,
whether Vical or its collaborative partners will seek or gain approval to
market any product candidates, the dependence of the company on its
collaborative partners, and additional risks set forth in the company's
filings with the Securities and Exchange Commission. These forward-looking
statements represent the company's judgment as of the date of this release.
The company disclaims, however, any intent or obligation to update these
forward-looking statements.

CONTACT: Alan R. Engbring
         (858) 646-1127

Vical Logo
Press spacebar to pause and continue. Press esc to stop.